These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 408838)

  • 21. Long-term depot neuroleptic treatment with perphenazine decanoate. I. Efficacy and side effects in a 12 month study of 42 drug monitored psychotic patients.
    Knudsen P; Hansen LB; Højholdt K; Larsen NE
    Acta Psychiatr Scand Suppl; 1985; 322():29-40. PubMed ID: 3907279
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Perphenazine decanoate and cis(z)-flupentixol decanoate in maintenance treatment of schizophrenic outpatients. Serum levels at the minimum effective dose.
    Kistrup K; Gerlach J; Aaes-Jørgensen T; Larsen NE
    Psychopharmacology (Berl); 1991; 105(1):42-8. PubMed ID: 1745710
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of simultaneous treatment with low doses of perphenazine on plasma and urine concentrations of nortriptyline and 10-hydroxynortriptyline.
    Kragh-Sorensen P; Borgå O; Garle M; Bolvig Hansen L; Hansen CE; Hvidberg EF; Larsen NE; Sjöqvist F
    Eur J Clin Pharmacol; 1977 Jul; 11(6):479-83. PubMed ID: 891595
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Perphenazine enanthate. Results of a 1-year open multicenter study].
    Baruch P; Brion S; Broussolle P; Gayral LF; Ropert R; Volmat R; Porot M
    Encephale; 1989; 15(5):449-55. PubMed ID: 2686965
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral intake of perphenazine decanoate.
    Larsen NE
    Ther Drug Monit; 1998 Dec; 20(6):724. PubMed ID: 9853996
    [No Abstract]   [Full Text] [Related]  

  • 26. Comparison of conventional neuroleptic therapy with depot neuroleptics. An attempt at economic evaluation.
    Lindholm H; Ljungberg L
    Acta Psychiatr Scand Suppl; 1973; 246():52-6. PubMed ID: 4520279
    [No Abstract]   [Full Text] [Related]  

  • 27. Comparison of perphenazine and P-5227 in chronic schizophrenics: clinical and EEG effects.
    Holden JM; Itil TM; Keskiner A
    J Clin Pharmacol J New Drugs; 1969; 9(3):163-75. PubMed ID: 5255181
    [No Abstract]   [Full Text] [Related]  

  • 28. [Technic and role of neuroleptic treatment with perphenazine in psychiatry].
    Ropert R
    Psychopharmacologie; 1971; ():71-82. PubMed ID: 5162009
    [No Abstract]   [Full Text] [Related]  

  • 29. Amorphous nanoparticle complex of perphenazine and dextran sulfate as a new solubility enhancement strategy of antipsychotic perphenazine.
    Dong B; Hadinoto K
    Drug Dev Ind Pharm; 2017 Jun; 43(6):996-1002. PubMed ID: 28121189
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Urinary excretion of perphenazine and its sulfoxide during administration in oral and long-acting injectable form.
    van Kempen GM
    Psychopharmacologia; 1971; 21(3):283-6. PubMed ID: 5095416
    [No Abstract]   [Full Text] [Related]  

  • 31. Development and validation of a gas chromatographic-mass spectrometric method for quantitative determination of perphenazine in rabbit plasma after sublingual administration.
    Turunen E; Lehtonen M; Järvinen T; Jarho P
    J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Sep; 872(1-2):51-7. PubMed ID: 18667368
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Perphenazine enantate in long-term therapy of psychoses].
    Gunby B
    Nord Psykiatr Tidsskr; 1968; 22(4):358-60. PubMed ID: 5710606
    [No Abstract]   [Full Text] [Related]  

  • 33. [Clinical experiences with perphenazine enanthate].
    Rafter B
    Nord Psykiatr Tidsskr; 1971; 25(4):371-4. PubMed ID: 5154124
    [No Abstract]   [Full Text] [Related]  

  • 34. [Results of treatment of schizophrenic and schizoaffective patients with sulpiride (Eglonyl Alkaloid) in comparison with perphenazine (Perfenazin Spofa)].
    Svestka J; Rysánek R; Náhunek K; Cesková E
    Cesk Psychiatr; 1990 Jun; 86(3):145-56. PubMed ID: 2225184
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acute neuroleptic treatment in elderly patients without dementia.
    Mazure CM; Nelson JC; Jatlow PI; Bowers MB
    Am J Geriatr Psychiatry; 1998; 6(3):221-9. PubMed ID: 9659955
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Perphenazine. Indications].
    Van Steenkiste J
    Psychopharmacologie; 1971; ():63-70. PubMed ID: 5162008
    [No Abstract]   [Full Text] [Related]  

  • 37. The pharmacokinetics of cimetidine and its sulphoxide metabolite in patients with normal and impaired renal function.
    Larsson R; Erlanson P; Bodemar G; Walan A; Bertler A; Fransson L; Norlander B
    Br J Clin Pharmacol; 1982 Feb; 13(2):163-70. PubMed ID: 7059413
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Perphenazine decanoate vs. perphenazine enanthate: efficacy and side effects in a 6 week double-blind, comparative study of 50 drug monitored psychotic patients.
    Knudsen P; Hansen LB; Auken G; Waehrens J; Højholdt K; Larsen NE
    Acta Psychiatr Scand Suppl; 1985; 322():15-28. PubMed ID: 3907278
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An open-label tolerability study of BL-1020 antipsychotic: a novel gamma aminobutyric acid ester of perphenazine.
    Anand R; Geffen Y; Vasile D; Dan I
    Clin Neuropharmacol; 2010; 33(6):297-302. PubMed ID: 20921890
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dissociation between the mammotrophic and galactopoietic effects of perphenazine and perphenazine sulphoxide in the rat.
    Weller CP; Mishkinsky JS; Givant Y; Sulman FG
    Arch Int Pharmacodyn Ther; 1972 Dec; 200(2):405-14. PubMed ID: 4566854
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.